The Monoclonal Antibodies Quality & Regulatory Requirements conference is an advanced pharmaceutical and biotechnology training program focused on the latest developments in biologics quality standards, regulatory compliance, and monoclonal antibody manufacturing strategies. As monoclonal antibodies (mAbs), biosimilars, bispecific antibodies, and antibody-drug conjugates continue to transform the global biopharmaceutical industry, regulatory expectations for product quality, analytical characterization, process validation, and lifecycle management are becoming increasingly complex.
This comprehensive conference delivers in-depth insights into global regulatory frameworks, including updated International Council for Harmonisation guidance, Quality by Design (QbD), comparability protocols, process characterisation, and manufacturing control strategies for biologics. Participants will gain practical knowledge on BLA/MAA regulatory submissions, analytical product profiling, stability studies, continuous process verification, technology transfer, and lifecycle management approaches aligned with current U.S. Food and Drug Administration and European Medicines Agency expectations.
The conference agenda includes expert-led sessions, real-world case studies, interactive discussions, and practical implementation strategies designed to help professionals manage manufacturing challenges, maintain GMP compliance, and optimize regulatory readiness throughout the biologics product lifecycle. Special focus areas include biosimilars development, glycosylation effects in monoclonal antibodies, process change management, analytical methods lifecycle management, and advanced manufacturing approaches for commercial biopharmaceutical production.
Designed for professionals working in quality assurance, regulatory affairs, analytical development, manufacturing, R&D, and CMC within the pharmaceutical and biotechnology industries, this conference provides a valuable platform for networking, knowledge exchange, and learning from experienced industry experts with extensive regulatory and manufacturing expertise.
This conference is designed for pharmaceutical, biotechnology, and biologics industry professionals involved in monoclonal antibodies development, regulatory compliance, quality management, and manufacturing operations.
The program is particularly beneficial for:
- Quality Assurance (QA) & Quality Control (QC) professionals
- Regulatory Affairs specialists
- CMC (Chemistry, Manufacturing & Controls) experts
- Analytical Development scientists
- Biopharmaceutical Manufacturing professionals
- Process Development & Validation teams
- Research & Development (R&D) professionals
- GMP compliance and auditing specialists
- Biosimilars and biologics development teams
- Technology transfer and lifecycle management professionals
- Pharmaceutical and biotechnology consultants
- Scientists working with monoclonal antibodies, ADCs, bispecific antibodies, and fusion proteins
Attendees will gain practical insights into International Council for Harmonisation guidelines, biologics regulatory expectations, process validation strategies, analytical characterization, comparability studies, and lifecycle management for advanced monoclonal antibody products.